Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Celitec
Gaithersburg, Maryland, United Statescelitech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Celitech is a clinical-stage biotechnology company focused on developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematologic malignancies and solid tumors. The company utilizes its proprietary Celi-CAR platform to engineer T-cells with enhanced persistence and anti-tumor activity, aiming to overcome the limitations of current cell therapies. Its lead programs target well-validated antigens such as CD19 and BCMA, with clinical trials underway for various B-cell lymphomas and multiple myeloma. Celitech is headquartered in Maryland and maintains a focus on streamlining the manufacturing process to improve patient access to advanced immunotherapies.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Celitec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celitec.